This ‘Respiratory syncytial virus (RSV) Overview - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the Respiratory syncytial virus (RSV) historical and forecasted epidemiology as well as the RSV epidemiology trends in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.
RSV is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus. Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F. Signs and symptoms of RSV infection most commonly appears about 4-6 days after exposure to the virus. RSV usually causes mild cold-like signs and symptoms in adults and older children. Signs and symptoms of severe RSV infection in infants include rapid breathing, cough, poor feeding, irritability, and unusual tiredness.
Geographies Covered
- The United States
- EU4 (Germany, France, Italy, Spain) and the UK
- Japan
Respiratory syncytial virus (RSV) Understanding
This Respiratory syncytial virus (RSV) report gives a thorough understanding of RSV by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.RSV is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human RSV, bovine RSV, and murine pneumonia virus. Two major antigenic subtypes of human RSV (A and B) are determined mainly by antigenic drift and duplications in RSV-G sequences but accompanied by genome-wide sequence divergence, including within RSV-F. Signs and symptoms of RSV infection most commonly appears about 4-6 days after exposure to the virus. RSV usually causes mild cold-like signs and symptoms in adults and older children. Signs and symptoms of severe RSV infection in infants include rapid breathing, cough, poor feeding, irritability, and unusual tiredness.
Diagnosis
Testing for Respiratory syncytial virus (RSV) is often unnecessary; if required, several types of laboratory tests are used for diagnosis. The most commonly used is the rapid diagnostic test that looks for RSV antigens in nasal secretions. If the rapid test is negative, the doctor may order a virus culture of the secretions. The doctor may also choose a more sensitive test that uses genetic technology to detect the virus in the blood. Laboratory tests for RSV include rapid antigen detection tests (RADTs), direct fluorescent antibody (DFA), polymerase chain reaction (PCR), and viral cultures. Other tests include blood tests, chest X-rays, and pulse oximetry.Respiratory syncytial virus (RSV) Epidemiology
The Respiratory syncytial virus (RSV) epidemiology section provides insights into the historical and current RSV patient pool and forecasted trends for individual seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.Key Findings
- In 2022, the total incident cases of Respiratory syncytial virus (RSV) in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
- Total incident cases of RSV were highest in those below 5 years, followed by 65 years and above, and the least number of cases were found in the 5-64 years age group.
- The United States comprised ~58% of the total incident RSV cases in the 7MM in 2022.
- EU4, the UK, and Japan contributed ~30% and 12% to the total incident pool of RSV in 2022.
- In 2022, as per the severity of RSV infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of RSV in the US, respectively.
- The visit-specific distribution of RSV was further bifurcated into hospitalization and outpatient, making 7% and 93% of the treated cases of RSV in the US, respectively, in 2022.
- Due to the COVID-19 pandemic impact, a declining trend was observed in the RSV cases in 2020 across the 7MM countries. However, currently, the immunity gap developed due to the COVID-19 pandemic is proliferating the trend of RSV cases across the globe, leading to a sudden burden on healthcare systems.
Country Wise Respiratory syncytial virus (RSV) Epidemiology
This section provides a glimpse of the Respiratory syncytial virus (RSV) epidemiology in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.Scope of the Report
- The report covers a descriptive overview of the Respiratory syncytial virus (RSV), explaining its procedure, types, indications, and currently available therapies.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.
- The report assesses the RSV risk and burden.
- The report provides the segmentation of the epidemiology for the 7MM by segmented by Total Incident Cases of RSV, Age-specific Incident Cases of RSV, Severity-specific Incident Cases of RSV in children, Severity-specific Incident Cases of RSV in adults, and Visit-specific Incident Cases of RSV in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.
Report Highlights
- 10-Year Forecast of Respiratory syncytial virus (RSV)
- The 7MM Coverage
- Total Incident Cases of RSV
- Age-specific Incident Cases of RSV
- Severity-specific Incident Cases of RSV in children
- Severity-specific Incident Cases of RSV in adults
- Visit-specific Incident Cases of RSV
Key Questions Answered
- What are the risk, burdens, and unmet needs of Respiratory syncytial virus (RSV)?
- What is the historical RSV patient pool in the 7MM?
- What would be the forecasted patient pool of RSV at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to RSV?
- At what CAGR is the population expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Respiratory syncytial virus (RSV) report will allow the user to:- Develop business strategies by understanding the trends, shaping and driving the 7MM RSV epidemiology.
- The RSV epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The RSV epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Table of Contents
1. Key Insights2. Report Introduction
3. Respiratory Syncytial Virus (RSV) Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Respiratory Syncytial Virus (RSV) in the 7MM in 2019
3.2. Patient Share (%) Distribution of Respiratory Syncytial Virus (RSV) in the 7MM by 2032
4. Executive Summary of Respiratory Syncytial Virus (RSV)
5. Key Events
6. Disease Background and Overview
6.1. Introduction
6.1.1. Structure of RSV
6.1.2. Transmission of RSV
6.1.3. Replication of RSV
6.2. Pathophysiology
6.3. Signs and Symptoms
6.4. Diagnosis
7. Methodology
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Total Incident Cases of Respiratory Syncytial Virus (RSV) in the 7MM
8.4. The United States
8.4.1. Total Incident Cases of Respiratory Syncytial Virus (RSV) in the United States
8.4.2. Age-specific Incident Cases of Respiratory Syncytial Virus (RSV) in the United States
8.4.3. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Children in the United States
8.4.4. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Adults in the United States
8.4.5. Visit-specific Incident Cases of Respiratory Syncytial Virus (RSV) in the United States
8.5. EU4 and the UK Epidemiology
8.5.1. Total Incident Cases of Respiratory Syncytial Virus (RSV) in EU4 and the UK
8.5.2. Age-specific Incident Cases of Respiratory Syncytial Virus (RSV) in EU4 and the UK
8.5.3. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Children in EU4 and the UK
8.5.4. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Adults in EU4 and the UK
8.5.5. Visit-specific Incident Cases of Respiratory Syncytial Virus (RSV) in EU4 and the UK
8.6. Japan
8.6.1. Total Incident Cases of Respiratory Syncytial Virus (RSV) in Japan
8.6.2. Age-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Japan
8.6.3. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Children in Japan
8.6.4. Severity-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Adults in Japan
8.6.5. Visit-specific Incident Cases of Respiratory Syncytial Virus (RSV) in Japan
9. Appendix
9.1. Report Methodology
9.2. Bibliography
10. Publisher Capabilities
11. Disclaimer
12. About the Publisher
List of Tables
Table 1: Summary of Respiratory Syncytial Virus (2019-2032)
Table 2: Key Events
Table 3: Diagnosed Incident Cases of Respiratory syncytial virus (RSV) in the 7MM in ‘000 (2019-2032)
Table 4: Total Incident Cases of Respiratory syncytial virus (RSV) in the United States in ‘000 (2019-2032)
Table 5: Total Incident Cases of Respiratory syncytial virus (RSV) in the United States in ‘000 (2019-2032)
Table 6: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in the United States in ‘000 (2019-2032)
Table 7: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in the United States in ‘000 (2019-2032)
Table 8: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in the United States in ‘000 (2019-2032)
Table 9: Total Incident Cases of Respiratory syncytial virus (RSV) in EU4 and the UK in ‘000 (2019-2032)
Table 10: Age-specific Incident Cases of Respiratory syncytial virus (RSV) in EU4 and the UK in ‘000 (2019-2032)
Table 11: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in EU4 and the UK in ‘000 (2019-2032)
Table 12: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in EU4 and the UK in ‘000 (2019-2032)
Table 13: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in EU4 and the UK in ‘000 (2019-2032)
Table 14: Diagnosed Incident Cases of Respiratory syncytial virus (RSV) in Japan in ‘000 (2019-2032)
Table 15: Age-specific Incident Cases of Respiratory syncytial virus (RSV) in Japan in ‘000 (2019-2032)
Table 16: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in Japan in ‘000 (2019-2032)
Table 17: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in Japan in ‘000 (2019-2032)
Table 18: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in adults Japan in ‘000 (2019-2032)
List of Figures
Figure 1: RSV Genome and Proteins
Figure 2: Replication Cycle of RSV
Figure 3: Viral, Host, and Environmental Factors Involved in RSV Pathogenesis
Figure 4: Pathogenesis Cycle of RSV
Figure 5: Signs and Symptoms in Mild Cases of RSV
Figure 6: Signs and Symptoms in Severe Cases of RSV in Adults
Figure 7: Signs and Symptoms in Severe Cases of RSV in Infants
Figure 8: Total Incident Cases of Respiratory syncytial virus (RSV) in the 7MM in ‘000 (2019-2032)
Figure 9: Total Incident Cases of Respiratory syncytial virus (RSV) in the United States in ‘000 (2019-2032)
Figure 10: Total Incident Cases of Respiratory syncytial virus (RSV) in the United States in ‘000 (2019-2032)
Figure 11: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in the United States in ‘000 (2019-2032)
Figure 12: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in the United States (2019-2032)
Figure 13: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in the United States in ‘000 (2019-2032)
Figure 14: Total Incident Cases of Respiratory syncytial virus (RSV) in EU4 and the UK in ‘000 (2019-2032)
Figure 15: Age-specific Incident Cases of Respiratory syncytial virus (RSV) in EU4 and the UK in ‘000 (2019-2032)
Figure 16: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in EU4 and the UK in ‘000 (2019-2032)
Figure 17: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in EU4 and the UK in ‘000 (2019-2032)
Figure 18: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in EU4 and the UK in ‘000 (2019-2032)
Figure 19: Total Incident Cases of Respiratory syncytial virus (RSV) in Japan in ‘000 (2019-2032)
Figure 20: Age-specific Incident Cases of Respiratory syncytial virus (RSV) in Japan in ‘000 (2019-2032)
Figure 21: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in children in Japan in ‘000 (2019-2032)
Figure 22: Severity-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in Japan in ‘000 (2019-2032)
Figure 23: Visit-specific Incident Cases of Respiratory syncytial virus (RSV) in adults in Japan in ‘000 (2019-2032)
